Beyond the FDA PRO Guidance: Steps Toward Integrating Meaningful Patient-Reported Outcomes Into Regulatory Trials and US Drug Labels

Value in Health - United Kingdom
doi 10.1016/j.jval.2012.03.1385
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Patient-Reported Outcomes in Orphan Drug Labels Approved by the US FDA

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Responder Definition of a Patient-Reported Outcome Instrument for Laryngopharyngeal Reflux Based on the US FDA Guidance

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Patient Reported Outcomes (PROs) in Clinical Trials: Is ‘In-Trial’ Guidance Lacking? A Systematic Review

PLoS ONE
Multidisciplinary
2013English

FDA Reported Use of Patient Experience Data in 2018 Drug Approvals

Therapeutic Innovation and Regulatory Science
PharmacologyPublic HealthEnvironmentalToxicologyPharmaceuticsOccupational Health
2019English

Prs97 - Patient Reported Outcomes in Copd Clinical Trials: Trends and Gaps

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Measurement of Patient-Reported Outcomes. 2: Are Current Measures Failing Us?

Journal of Medical Economics
Health Policy
2019English

Correction To: Trials With Patient-Reported Outcomes Registered on the Australian New Zealand Clinical Trials Registry (ANZCTR)

Quality of Life Research
EnvironmentalPublic HealthOccupational Health
2018English

Development and Validation of a Primary Sclerosing Cholangitis-Specific Patient-Reported Outcomes Instrument: The PSC PRO

Hepatology
MedicineHepatology
2018English

Measuring Patient-Reported Outcomes: Moving Beyond Misplaced Common Sense to Hard Science

BMC Medicine
Medicine
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy